Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
종목 코드 CELG_r
회사 이름Bristol-Myers Squibb Co
상장일Mar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
직원 수- -
유형- -
회계 연도 종료- -
주소Route 206 And Province Line Road
도시PRINCETON
증권 거래소- -
국가United States of America
우편 번호08543
전화16092524621
웹사이트https://www.bms.com
종목 코드 CELG_r
상장일Mar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음